Renalytix reports positive study on clinical value of KidneyIntelX
Sharecast
Published Apr 19, 2023 13:38
Updated Apr 19, 2023 14:13
Renalytix reports positive study on clinical value of KidneyIntelX
Sharecast - The AIM-traded firm said the study emphasised the importance of early risk assessment to reduce the likelihood of progression to kidney failure and dialysis.
It said the case studies were carried out by a multidisciplinary clinical advisory panel that examined four different physicians' management of four patient cases using KidneyIntelX.
The study identified the lack of CKD education and patient awareness as barriers to care management in primary care settings.
It also emphasised the need for type-2 diabetic patients to learn about CKD management to improve health behaviour and medication compliance.
The study also noted that the lack of risk assessment tools in primary care often prevented the identification of high-risk patients in the early stages of CKD.
It described KidneyIntelX as a “bioprognostic tool” incorporating well-validated prognostic protein biomarkers, which could help to predict rapid kidney function decline in early-stage CKD patients.
The board said the proactive approach would help clinicians to optimise care and change the trajectory of chronic kidney disease before the onset of severe or irreversible kidney damage.
“This independent review reinforces the importance of KidneyIntelX early prognosis in patients with kidney disease and type-2 diabetes,” said the company’s chief medical officer Michael Donovan.
“These utility results were well represented in 'real-time' with the reported case studies and the introduction of the KidneyIntelX bioprognosis supporting clinical decision making and care optimisation across a spectrum of kidney event risk.”
At 1238 BST, shares in Renalytix were flat at 93p.
Reporting by Josh White for Sharecast.com.
Read more on Sharecast.com
Get The App
Written By: Sharecast
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.